Pharmaceutical giant Pfizer and French partner Valneva on Monday said they planned to seek regulatory approval for a Lyme disease vaccine after a late-stage trial.
Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial
Related Posts
Popular News
Latest News
Senators to Introduce Bill to Ban Sports Betting on Prediction Markets
US Senators Adam Schiff and John Curtis are expected to introduce a bipartisan bill on Monday that would bar sports...
BlackRock’s Larry Fink warns against trying to time the market
Larry Fink, Chairman and CEO of BlackRock, speaks during an interview with CNBC on the floor at the New York...
Chamonix completes $304m inaugural project finance CLO
Chamonix Partners Capital Management has raised $304m (£228.9m) for its inaugural project finance collateralised loan obligation (CLO). The Chamonix Infrastructure...
Airbnb’s Latest Iconic Stay: A Night Inside Mexico City’s Football Stadium—And World Cup Tickets
For travelers with an eye on the 2026 FIFA World Cup, today marks a rare chance to secure access to...
Welcome to Global Finances Daily, your go-to source for all things finance. Our mission is to provide our readers with valuable information and insights to help them achieve their financial goals and secure their financial future.